@Dux4896 @Blackouts @Ron_Burgundy_ @glimdbea
“if” they receive FDA approval this week and then EU, they’re going to knock sales out of the park imo (this will be the first drug ever approved in PFIC 1,2 & 3). Then you have P3 data in AS, all their trial data has been outstanding. Their pipeline is getting deeper. I’ll say again, I could see this on a similar trajectory as BCRX, both drugs are close in price too imo. I look at market cap, no reason to think if all the above hits for ALBO that it doesn’t hold a $2 B + mkt cap in the next 6-7 months. This was BCRX mkt cap before approval & as if Friday. Again not saying 100% apples to apples, but good example what happens with a drug for a rare disease that works combined with strong management. It all starts with approval and yes stocks do go up and down, but overall trend will continue up for ALBO.